Andrew holds the position of General Manager at Shanghai Wotai Biotechnology, a Walvax subsidiary, and is the Director of Business Development at Walvax Biotechnology Ltd. He sustains more than 30 years of intercultural experience on molecular cancer drug, antibody therapeutics, human vaccine research, business development, global registration, and sales & marketing. Through Andrew’s leadership and participation, Walvax and its subsidiary companies have received several grants and/or technical supports from DCVMN, Bill & Melinda Gates Foundation, PATH, CEPI and CHAI since 2014, in addition to the global business expansion of product registration and sales in numerous countries.